88 related articles for article (PubMed ID: 1751199)
1. Endothelin and platelet activating factor. Possible indices for biocompatibility of hemodialysis.
Akizawa T; Kinugasa E; Koshikawa S
ASAIO Trans; 1991; 37(3):M384-5. PubMed ID: 1751199
[TBL] [Abstract][Full Text] [Related]
2. Platelet-neutrophil interactions during hemodialysis: a proposed biocompatibility approach.
Stuard S; Bonomini M; Settefrati N; Albertazzi A
Int J Artif Organs; 1998 Feb; 21(2):75-82. PubMed ID: 9569128
[TBL] [Abstract][Full Text] [Related]
3. Is platelet-activating factor produced during hemodialysis with AN-69 polyacrylonitrile membrane?
Iatrou C; Afentakis N; Nomikos T; Dinas C; Stavropoulos-Giokas C; Antonopoulou S
Nephron; 2002 May; 91(1):86-93. PubMed ID: 12021524
[TBL] [Abstract][Full Text] [Related]
4. The production of platelet-activating factor (PAF) during hemodialysis with cuprophane membrane. Does the calcium concentration in the dialysate play any role on it?
Iatrou C; Afentakis N; Antonopoulou S; Andrikopoulos N; Demopoulos CA; Ziroyannis P
Int J Artif Organs; 1995 Jul; 18(7):355-61. PubMed ID: 8655220
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 8 and biocompatibility of dialysis membranes.
Niwa T; Miyazaki T; Sato M; Kambe F; Tsuzuki T; Uema K; Maeda K; Seo H
Am J Nephrol; 1995; 15(3):181-5. PubMed ID: 7618641
[TBL] [Abstract][Full Text] [Related]
6. Effect of hemodialysis on plasma levels of vasoactive peptides: endothelin, calcitonin gene-related peptide and human atrial natriuretic peptide.
Niwa T; Fujishiro T; Uema K; Tsuzuki T; Tominaga Y; Emoto Y; Miyazaki T; Maeda K
Nephron; 1993; 64(4):552-9. PubMed ID: 8366980
[TBL] [Abstract][Full Text] [Related]
7. 8-hydroxy-2'-deoxyguanosine of leukocyte DNA as a marker of oxidative stress in chronic hemodialysis patients.
Tarng DC; Huang TP; Wei YH; Liu TY; Chen HW; Wen Chen T; Yang WC
Am J Kidney Dis; 2000 Nov; 36(5):934-44. PubMed ID: 11054349
[TBL] [Abstract][Full Text] [Related]
8. The production of platelet-activating factor during hemodialysis.
Tetta C; Segoloni G; Pacitti A; Regis G; Salomone M; Turello E; Camussi G; Vercellone A
Int J Artif Organs; 1989 Dec; 12(12):766-72. PubMed ID: 2613357
[TBL] [Abstract][Full Text] [Related]
9. Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension.
Cases A; Esforzado N; Lario S; Vera M; Lopez-Pedret J; Rivera-Fillat F; Jimenez W
Kidney Int; 2000 Feb; 57(2):664-70. PubMed ID: 10652045
[TBL] [Abstract][Full Text] [Related]
10. Biocompatibility and clinical performance of a new modified cellulose membrane.
Bosch T; Schmidt B; Samtleben W; Gurland HJ
Clin Nephrol; 1986; 26 Suppl 1():S22-9. PubMed ID: 3829464
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of biocompatibility of hemophane, cellulose diacetate and acrilonitile membranes in hemodialysis].
Germin Petrović D
Acta Med Croatica; 2004; 58(1):31-6. PubMed ID: 15125391
[TBL] [Abstract][Full Text] [Related]
12. Increases in circulating level of platelet-activating factor lag behind transient neutropenia during hemodialysis with cuprophane membranes.
Sakaguchi K; Morimoto S; Chen YH; Nakamoto Y; Ogihara T
Nephron; 1991; 59(3):455-60. PubMed ID: 1758537
[TBL] [Abstract][Full Text] [Related]
13. Changes in endothelial vasoactive substances under recombinant human erythropoietin therapy in hemodialysis patients.
Takayama K; Nagai T; Kinugasa E; Akizawa T; Koshikawa S
ASAIO Trans; 1991; 37(3):M187-8. PubMed ID: 1836334
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of a polyethylene glycol grafted cellulose membrane on thrombogenicity and biocompatibility during hemodialysis.
Akizawa T; Kino K; Kinugasa E; Koshikawa S; Ikada Y; Kishida A; Hatanaka Y; Imamura K
ASAIO Trans; 1990; 36(3):M640-2. PubMed ID: 2252772
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms and kinetics of the synthesis and release of platelet-activating factor (PAF) by polyacrylonitrile membranes.
Guastoni C; Tetta C; Hoenich NA; Gervasio R; Sereni L; Tessore E; Wratten ML; Civati G
Clin Nephrol; 1996 Aug; 46(2):132-8. PubMed ID: 8869791
[TBL] [Abstract][Full Text] [Related]
16. Biocompatibility of dialysis membranes is of no importance for objective or subjective symptoms during or after hemodialysis.
Skroeder NR; Jacobson SH; Lins LE; Kjellstrand CM
ASAIO Trans; 1990; 36(3):M637-9. PubMed ID: 2252771
[TBL] [Abstract][Full Text] [Related]
17. Effect of vitamin E-bonded membrane on the 8-hydroxy 2'-deoxyguanosine level in leukocyte DNA of hemodialysis patients.
Tarng DC; Huang TP; Liu TY; Chen HW; Sung YJ; Wei YH
Kidney Int; 2000 Aug; 58(2):790-9. PubMed ID: 10916104
[TBL] [Abstract][Full Text] [Related]
18. The role of PAF and leukotrienes in bioincompatibility of cuprophane membranes in hemodialysis.
Kabasakal C; Mir S; Gousseinov A; Cura A; Betin N; Coker I
Turk J Pediatr; 1998; 40(3):413-20. PubMed ID: 9763906
[TBL] [Abstract][Full Text] [Related]
19. Relationship between volume status and blood pressure during chronic hemodialysis.
Leypoldt JK; Cheung AK; Delmez JA; Gassman JJ; Levin NW; Lewis JA; Lewis JL; Rocco MV
Kidney Int; 2002 Jan; 61(1):266-75. PubMed ID: 11786109
[TBL] [Abstract][Full Text] [Related]
20. The effects of hemodialysis (HD) membranes on interleukin 1-beta (IL-1 beta) production from peripheral blood mononuclear cells (PBMC).
Momoi T; Ono M; Takagi T; Sugiura S; Ogawa H; Saito A
Clin Nephrol; 1995 Nov; 44 Suppl 1():S24-8. PubMed ID: 8608657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
